Stanford University School of Medicine, Dept. of Psychiatry and Behavioral Sciences
Stanford, California, 94070-5723, United States
NCT Number: NCT00097058
This study is designed to assess the effects of estrogen therapy among postmenopausal women at risk for cognitive decline.
Looking for future studies?
Notify Me45 year–65 year
Female
Observational
Stanford, California, 94070-5723, United States
A total of 71 postmenopausal women ages 50-65 on estrogen therapy will be randomized to continue or discontinue use of estrogen and will be followed for two years.
Participants will undergo PET and MRI scans and neuropsychological assessments initially and at the end of the two-year follow-up period. These procedures will allow us to evaluate brain metabolism and cognitive performance at baseline and two years following continuation or discontinuation of estrogen therapy.
We hypothesize that women who discontinue estrogen will show more evidence of decline than those who continue estrogen. This project will expand current knowledge of effects of estrogen by 1) determining whether estrogen use among postmenopausal women at risk for cognitive decline is protective of brain metabolism, 2) identifying early predictors for cognitive decline, and 3) developing guidelines for estrogen use in postmenopausal women.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Baseline and 24 months
Stanford University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05023187
Aging, Cognition Disorders
Rovereto, Trento, Italy
View Trial DetailsNCT06977815
Aging, Cognition Disorders
Badalona, Barcelona, Spain
View Trial DetailsNCT07643675
Aging, Cognition Disorders
México, State of Mexico, Mexico
View Trial DetailsNCT05380180
Aging, Aging Well
Champaign, Illinois, United States
View Trial Details